HIMS

31.22

0.55% 0.17

Pre-market: 29.23 -1.99 -6.37%

Hims Hers Health Inc (HIMS)

Overview News Price History Option Chain Financials Why HIMS Down? Discussions Forecast

Hims Hers Health Inc stock is traded at $31.22, with a volume of 24.63M. It is up +0.55% in the last 24 hours and down -30.76% over the past month.

Previous Close:

$31.05

Open:

$29.16

24h Volume:

24.63M

Relative Volume:

1.16

Market Cap:

$6.90B

Revenue:

$1.24B

Net Income/Loss:

$101.26M

P/E Ratio:

70.95

EPS:

0.44

Net Cash Flow:

$149.62M

1W Performance:

-6.41%

1M Performance:

-30.76%

6M Performance:

+64.75%

1Y Performance:

+108.27%

1-Day Range:

$28.95

$31.25

1-Week Range:

$27.22

$33.70

52-Week Range:

$11.20

$72.98

Hims Hers Health Inc Stock (HIMS) Company Profile

Name

Hims Hers Health Inc

Sector

Consumer Defensive (243)

Industry

Household & Personal Products (32)

Phone

415-851-0195

Address

2269 CHESTNUT ST, SAN FRANCISCO

Employee

Twitter

Next Earnings Date

2025-02-24

Latest SEC Filings

HIMS's Discussions on Twitter

Compare HIMS with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HIMS Hims Hers Health Inc	31.22	6.90B	1.24B	101.26M	149.62M	0.44
PG Procter Gamble Co	169.50	399.94B	84.35B	15.48B	15.47B	6.28
UL Unilever Plc Adr	59.86	149.16B	65.10B	6.16B	0	2.4569
CL Colgate Palmolive Co	93.55	76.72B	20.10B	2.89B	3.55B	3.52
KMB Kimberly Clark Corp	142.90	47.44B	20.06B	2.55B	2.51B	7.55
KVUE Kenvue Inc	23.87	45.64B	15.46B	1.03B	1.34B	0.53

Hims Hers Health Inc Stock (HIMS) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-18-25	Downgrade	Morgan Stanley	Overweight → Equal-Weight
Jan-10-25	Downgrade	Citigroup	Neutral → Sell
Jan-07-25	Initiated	BTIG Research	Buy
Dec-17-24	Initiated	Morgan Stanley	Overweight
Nov-14-24	Downgrade	BofA Securities	Buy → Underperform
Aug-22-24	Initiated	Needham	Buy
Aug-09-24	Downgrade	Imperial Capital	Outperform → In-line
May-22-24	Downgrade	Citigroup	Buy → Neutral
Apr-16-24	Downgrade	Jefferies	Buy → Hold
Apr-10-24	Initiated	Canaccord Genuity	Buy
Feb-28-24	Upgrade	Imperial Capital	In-line → Outperform
Feb-26-24	Initiated	Leerink Partners	Market Perform
Dec-07-23	Initiated	Imperial Capital	In-line
Jul-28-23	Initiated	TD Cowen	Outperform
Apr-11-23	Initiated	Robert W. Baird	Neutral
Feb-09-23	Upgrade	Jefferies	Hold → Buy
Nov-08-22	Upgrade	BofA Securities	Neutral → Buy
Nov-08-22	Upgrade	SVB Leerink	Mkt Perform → Outperform
Oct-17-22	Downgrade	Piper Sandler	Overweight → Neutral
Sep-07-22	Initiated	Truist	Hold
Jul-15-22	Initiated	SVB Leerink	Underperform
Apr-14-22	Initiated	Guggenheim	Buy
Apr-01-22	Resumed	Credit Suisse	Outperform
Mar-10-22	Initiated	Deutsche Bank	Hold
Dec-02-21	Initiated	Jefferies	Hold
Nov-11-21	Upgrade	Piper Sandler	Neutral → Overweight
Jul-06-21	Initiated	BofA Securities	Neutral
May-20-21	Upgrade	Credit Suisse	Neutral → Outperform
Apr-21-21	Initiated	Truist	Hold
Mar-09-21	Initiated	Credit Suisse	Neutral
Mar-02-21	Upgrade	Citigroup	Neutral → Buy
Feb-17-21	Initiated	Citigroup	Neutral
Feb-12-21	Initiated	Piper Sandler	Neutral
Feb-08-21	Initiated	Tigress Financial	Buy

View All

Hims Hers Health Inc Stock (HIMS) Latest News

Apr 02, 2025

Why Hims & Hers Health Stock Couldn't Beat the Market Today - MSN

Apr 02, 2025

Why Hims & Hers Health Stock Couldn't Beat the Market Today - The Motley Fool

Apr 02, 2025

Hims & Hers stock slipped as investors were left unimpressed with its new weight-loss drug options - Yahoo Finance

Apr 02, 2025

Analysts Stay Cautious on HIMS Stock amid Core Business Uncertainty - The Globe and Mail

Apr 02, 2025

Hims & Hers Health's Launch of Liraglutide on Telehealth Platform Seen as 'Incrementally Positive,' Says Truist Securities - MarketScreener

Apr 02, 2025

Eli Lilly denies affiliation with Hims & Hers - Modern Healthcare

Apr 02, 2025

‘Too Hot to Handle,’ Analyst Warning on Hims & Hers Health Stock (HIMS) - TipRanks

Apr 02, 2025

Eli Lilly says it has “no affiliation” with Hims & Hers after market confusion - Sherwood News

Apr 02, 2025